Completed
Alternate Day Buprenorphine Administration, Phase IX
Led by University of Vermont · Updated on 2016-05-06
N/A
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Vermont
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.
CONDITIONS
Official Title
Alternate Day Buprenorphine Administration, Phase IX - 14
Who Can Participate
Eligibility Criteria
You may qualify if you...
Please contact site for information.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
Treatment Research Center
Burlington, Vermont, United States, 05401
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
N/A
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here